ISPOR 19th ANNUAL EUROPEAN CONGRESS DREW KEY STAKEHOLDERS AND THOUGHT LEADERS TO DISCUSS ACCESS TO MEDICAL INNOVATIONS

ISPOR 19th Annual European Congress

Regulatory, Policy, and Financing Decisions in International Health Systems
 

Princeton, NJ—November 22, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) recently concluded its 19th Annual European Congress in Vienna, Austria. More than 4,700 delegates—stakeholders from all sectors of health care, including health ministries and government offices, health technology assessment bodies, public and private payers, researchers and academics, patients and patient advocates—representing 89 countries convened on 29 October through 2 November 2016 to discuss access to medical innovations in Europe. Read more ›

Tagged with: , , , , , , , ,
Posted in Announcements, ISPOR News & Press

BEST PODIUM AND POSTER PRESENTATIONS AWARDED AT ISPOR 19TH ANNUAL EUROPEAN CONGRESS

Princeton, NJ—November 22, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) recognized the Best Podium Presentation and Best Poster Presentation Awardees at its 19th Annual European Congress in Vienna, Austria. Read more ›

Tagged with: ,
Posted in Announcements, ISPOR News & Press

ISPOR CEO NANCY BERG WINS SILVER STEVIE® AWARD IN 2016 STEVIE AWARDS FOR WOMEN IN BUSINESS

sawib16_silver_v_Large

Women Around the World Recognized at Event in New York City 

Princeton, NJ—November 21,  2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) CEO and Executive Director Nancy Berg has been named the winner of a Silver Stevie® Award in the Female Executive of the Year category in the 13th annual Stevie Awards for Women in Business. Read more ›

Tagged with: ,
Posted in Announcements, ISPOR News & Press

ISPOR LAUNCHES “NEW PROFESSIONALS” NETWORK

ISPOR New Professionals_2016-11-07

Membership Category Designed to Serve Future HEOR Leaders

Princeton, NJ—November 7, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced today the launch of its New Professionals Network. The new membership category was designed to serve the unique needs of future leaders in the field of health economics and outcomes research (HEOR). Read more ›

Tagged with:
Posted in Announcements, ISPOR News & Press

ISPOR 19TH ANNUAL EUROPEAN CONGRESS FOCUSES ON THE USE OF REAL-WORLD DATA IN HEALTH TECHNOLOGY ASSESSMENT

Vienna, Austria—2 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held an issue panel this afternoon entitled, Using Observational (Real-World) Data in Health Technology Assessment: Route to Confusion or Better Decisions? The session took place at the Society’s 19th Annual European Congress in Vienna, Austria.  Read more ›

Tagged with: , , , ,
Posted in Announcements, ISPOR News & Press

ISPOR RECOGNIZES FIVE DISTINGUISHED RECIPIENTS OF 2016 SERVICE AWARDS AT 19TH ANNUAL EUROPEAN CONGRESS

2016 Marilyn Dix Smith Leadership Award Honoree - J. Jaime Caro,  MDCM, FRCPC

Awards Recognize Excellence in HEOR 

Vienna, Austria—2 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) recognized recipients at its 19th Annual European Congress in Vienna, Austria. The ISPOR Awards Program is designed to foster and recognize excellence and outstanding technical achievement in health economics and outcomes research (HEOR). Read more ›

Tagged with: ,
Posted in Announcements, ISPOR News & Press

PLENARY 3 OF ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXPLORES KEY LESSONS FROM THE INTERQUALITY PROJECT

Tomasz Hermanowski, PhD, InterQuality Project Leader and Professor and Head, Department of Pharmacoeconomics, Medical University of Warsaw in Poland

Focus on How to Control Costs and Improve Access

Vienna, Austria—2 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) hosted its third plenary session, How to Control Costs and Improve Access to Medicines: Lessons from the InterQuality Project, at the Society’s 19th Annual European Congress in Vienna, Austria.  Read more ›

Tagged with: ,
Posted in Announcements, ISPOR News & Press

ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXAMINES INCLUSION OF FUTURE MEDICAL COSTS IN HEALTH TECHNOLOGY ASSESSMENT GUIDELINES

Vienna, Austria—2 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held an issue panel entitled, Should Health Technology Assessment Guidelines Recommend Inclusion of Future Medical Costs?, at the Society’s 19th Annual European Congress in Vienna, Austria.  Read more ›

Tagged with: , ,
Posted in Announcements, ISPOR News & Press

ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXPLORES THE ASPIRATIONAL AND PRACTICAL ELEMENTS OF GENERATING REAL-WORLD EVIDENCE

Vienna, Austria—1 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) hosted an issue panel this afternoon entitled, Real World Evidence to Support Value Proposition and Reimbursement at Launch: The Aspirational Meets the Impractical?, at the Society’s 19th Annual European Congress in Vienna, Austria.

The issue panel was moderated by Kari Edwards, PhD, Managing Partner, Harbinger Health, LLC, Los Angeles, CA, USA. Panelists for the session included:

  • Adrian R. Levy, PhD, Professor and Head, Community Health and Epidemiology, Dalhousie University, Nova Scotia, AL, Canada
  • Arie Barlev, PharmD, MS, Senior Director, Health Economics and Outcomes Research, Medivation, Inc., San Francisco, CA, USA
  • Andrew Briggs, DPhil, William R. Lindsay Chair of Health Economics and Professor of Health Economics, University of Glasgow, Glasgow, UK

The panelists explored the tension that exists between the aspirational and practical elements of generating real-world evidence in a timely fashion to support reimbursement for the launch of a new product launch. Kari Edwards, PhD presented a number of illustrative case studies to provide context and moderated the debate. Adrian R. Levy, PhD provided a payer perspective, arguing in favor of real-world evidence and noting that timely assessment of likely effectiveness would support reimbursement submissions upon product launch. Arie Barlev, PharmD, MS presented an industry view noting the practical challenges associated with collecting evidence within a short, post-approval timeframe, and highlighted the problem of selection bias when measuring relative effect in populations exposed to newly approved agents compared with standards of care. The final speaker, Andrew Briggs, DPhil, represented the health economics point of view and demonstrated the use of modeling techniques to exploit the rigorous nature of clinical trial data.

Additional information on the ISPOR 19th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORVienna.

###

Tagged with: , ,
Posted in Announcements, ISPOR News & Press

ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXAMINES VALUE ASSESSMENT OF TRANSFORMATIVE MEDICINES IN RARE DISEASES

Vienna, Austria—1 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) offered a thought-provoking issue panel, Valuing Transformative Medicines in Rare Diseases: Methods and Madness, at the Society’s 19th Annual European Congress in Vienna, Austria.

Paul Hodgkins, PhD, Vice President, Vertex Pharmaceuticals, Boston, MA, USA moderated the session. Panelists included:

  • Ron Akehurst, DSc, Strategic Director, BresMed Health Solutions, Sheffield, UK
  • Alastair Kent, OBE, Director, Genetic Alliance UK, London, UK
  • Maarten Postma, PhD, Professor Pharmacoeconomics, Pharmacy Department, University of Groningen, Groningen, The Netherlands

Innovative treatments for rare diseases are often transformative for patients. This is especially true if the therapy is the first to treat a disease’s underlying cause, said moderator Paul Hodgkins. It can, however, be difficult to demonstrate clinical benefit and cost effectiveness due to a number of research challenges such as small sample sizes in clinical trials and the lack of good outcome measures.

The question was raised, “Why should rare and/or ultra-rare conditions be treated any differently in health technology assessment than more common conditions?” Panelists examined the pros and cons of adhering to current methods and evidence standards versus employing alternative methodological approaches and data sources in rare disease treatment evaluation. Alastair Kent, OBE discussed the importance of patient values and priorities when developing rare disease treatments and outcome measures.

ISPOR offers a number of working groups and resources related to this topic, including:

Additional information on the ISPOR 19th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORVienna.

###

Tagged with: ,
Posted in Announcements, ISPOR News & Press
Categories
Follow ISPOR
RSS FeedFriend me on FacebookFollow my company on LinkedInFollow me on TwitterWatch me on YouTube